CClinicalTrials.gg
CompletedNCT05559840Updated Sep 29, 2022

S-Condom Uterine Tamponade in Controlling Atraumatic Postpartum Haemorrhage (PPH) - RCT

An interventional study of S-Condom Uterine Tamponade and Traditional condom catheter in Post Partum Hemorrhage, sponsored by Mamms Institute of Fistula and Womens Health. Completed. Open to female participants aged 18 Years to 49 Years. Per ClinicalTrials.gov, last updated 2022-09-29.

Sponsored by Mamms Institute of Fistula and Womens Health · Not applicable, Interventional, and Prevention

From the registry’s dates

  • Registered 5 years 8 months after the study started (first participant enrolled Jan 2017, registered Sep 2022).
Phase
Not applicable
Study type
Interventional
Enrollment
82
Allocation
Randomized
Ages
18 Years to 49 Years
Sex
Female
01

Study summary

A Randomized Controlled Non inferiority Trial will be conducted to see the feasibility, acceptability and efficacy of S-Condom Uterine Tamponade in women with atraumatic PPH and not responding to first line of treatment.

Read the detailed description

A Randomized Controlled Non inferiority Trial will be conducted to see the feasibility, acceptability and efficacy of S-Condom Uterine Tamponade in women with atraumatic PPH and not responding to first line of treatment. The women will be divided randomly into two groups, in both groups two condom tied on a catheter will be introduced inside the uterus. In one group (Control group), condom will be inflated with saline and in another group(study group) it will be inflated with air. Time required to stop bleeding will be measured for comparison. Data collected will be analyzed using a quantitative approach and the results will be presented in tables and graphs. If air media proved feasible, acceptable and effective the PPH management will be easier, cost-effective can make a great impact in reaching the target for reduction of maternal mortality in Bangladesh and other resource poor settings.

02

Conditions studied

  • Post Partum Hemorrhage

Keywords

  • Randomised controlled trial, S-condom, postpartum haemorrhage
03

In context

Postpartum Hemorrhage

445 studies on the registry are indexed under Postpartum Hemorrhage; 75 are open to participants now.

This study's enrollment of 82 is below the median of 148 across 340 interventional studies indexed under Postpartum Hemorrhage.

Browse Postpartum Hemorrhage studies →

Lead sponsor

This is the only study on the registry with Mamms Institute of Fistula and Womens Health as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 49 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Inclusion criteria

  • All women who presented with atraumatic postpartum hemorrhage, refractory to first-line treatment (uterine massage and oxytocin) and who will give their consent will be included in the study and will be randomized

Exclusion criteria

Exclusion Criteria:

  • Women known to have allergy to latex, or presenting with clinical chorioamnionitis or primary hemorrhage caused by cervical-vaginal lacerations, a uterine rupture, or a placenta accreta will be excluded.
05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
82 participants (actual)

Study arms

  • Active comparator
    Group I

    The control group (Group I) will be treated with condom catheter tamponade by inflating the condom with saline according to national protocol.

    Device: S-Condom Uterine Tamponade

  • Experimental
    Group II

    The study group (Group II) will receive condom catheter that will be inflated with air

    Device: Traditional condom catheter

Interventions

  • DeviceS-Condom Uterine Tamponade

    The condom catheter will be inflated with air

  • DeviceTraditional condom catheter

    The condom catheter will be inflated with saline following national protocol

06

What researchers measure

Primary outcomes

  1. Time required to stop bleeding

    Comparison of the average time to stop bleeding following the intervention and the control

    Time frame: 2 years

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No — We will not share individual participant data with other researchers. We will remove all personal identifier after assigning unique ids to each participant before data entry

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Sep 29, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05559840
Lead sponsor
Mamms Institute of Fistula and Womens Health
Collaborators
International Centre for Diarrhoeal Disease Research, Bangladesh
Responsible party
Dr. Sayeba Akhter (Professor, Mamms Institute of Fistula and Womens Health) — Principal investigator
First posted
Sep 29, 2022
Start date
Jan 1, 2017
Primary completion
Dec 31, 2019
Completion
Dec 31, 2019
Last update
Sep 29, 2022

Study contacts

Sayeba Akhter, Dr.
principal investigator · Mamms Institute of Fistula and Womens Health

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion